SRPT Q2 2020 Earnings — Sarepta Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SRPTSarepta Therapeutics, Inc.

$2B

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$137M+45.1% YoY

Gross Profit

$124M90.3% margin

Operating Income

-$138M-100.7% margin

Net Income

-$151M-109.8% margin

EPS (Diluted)

$-1.93

QoQ Revenue Growth

+20.8%

Cash Flow

Operating Cash Flow

-$108M

Free Cash Flow

-$127M

Stock-Based Comp.

$28M

Balance Sheet

Total Assets

$2.9B

Total Liabilities

$1.8B

Stockholders' Equity

$1.0B

Cash & Equivalents

$1.6B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$137M	$95M	+45.1%
Gross Profit	$124M	$79M	+57.5%
Operating Income	-$138M	-$275M	+49.8%
Net Income	-$151M	-$276M	+45.4%